Diabetes Mellitus, Type 2 Clinical Trials in San Antonio, Texas

6 studies are recruiting for diabetes mellitus, type 2 in San Antonio, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

   This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure. The purpose of this study is to find out if a medicine called vicadrostat, when taken with empaglif…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   IMA Clinical Research San Antonio, San Antonio, Texas

   Locations

   1142 in total

   Run by

   Boehringer Ingelheim

   See if you can join NCT07064473 on ClinicalTrials.gov

2. A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

   The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, San Antonio, Texas

   Locations

   230 in total

   Run by

   AstraZeneca

   See if you can join NCT07784270 on ClinicalTrials.gov

3. A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

   The study is testing UBT251 in participants with type 2 diabetes. The purpose of this clinical study is to find out if UBT251 is effective and safe for treating participants with type 2 diabetes. Participants will either get UBT251, UBT251 placebo, semaglutide, or semaglutide placebo. Which treatme…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Quality Research Inc, San Antonio, Texas

   Locations

   70 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07668388 on ClinicalTrials.gov

4. Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema

   The purpose of this clinical study is to look at the safety and tolerability of switching from semaglutide to CagriSema, for participants who have type 2 diabetes. All participants will get CagriSema, the treatment being tested. Participants will be in this clinical study for about 6 months.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   NE Clin Res of San Antonio, San Antonio, Texas

   Locations

   40 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07817251 on ClinicalTrials.gov

5. Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)

   HYPOTHESIS: Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) have distinct pathophysiologic etiologies. Therefore, therapeutic interventions designed to correct the specific underlying pathogenic abnormalities in IGT and IFG will be required to optimally prevent the progressive b…

   Stage

   Not phased

   Ages

   18 to 65

   Site

   The University of Texas Health Science Center at San Antonio, San Antonio, Texas

   Run by

   The University of Texas Health Science Center at San Antonio

   See if you can join NCT02969798 on ClinicalTrials.gov

6. ROME GS System Study

   The purpose of this clinical investigation is to demonstrate that the proposed physical changes to the ROME GS Sensor do not have any adverse impact on safety and performance when compared to the Eversense 365 Sensor.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Flourish Research - San Antonio, San Antonio, Texas

   Locations

   4 in total

   Run by

   Senseonics, Inc.

   See if you can join NCT07518004 on ClinicalTrials.gov